-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
China Pharma Holdings, Inc. (NYSEAMERICAN:CPHI) Short Interest Update
China Pharma Holdings, Inc. (NYSEAMERICAN:CPHI) Short Interest Update
China Pharma Holdings, Inc. (NYSEAMERICAN:CPHI – Get Rating) saw a significant drop in short interest during the month of December. As of December 30th, there was short interest totalling 244,600 shares, a drop of 51.8% from the December 15th total of 507,100 shares. Based on an average daily volume of 2,160,000 shares, the short-interest ratio is presently 0.1 days. Currently, 0.9% of the company's stock are short sold.
China Pharma Stock Performance
CPHI remained flat at $0.11 during trading on Wednesday. 1,588,857 shares of the company were exchanged, compared to its average volume of 1,853,631. The firm has a market capitalization of $5.43 million, a P/E ratio of -1.31 and a beta of 0.62. China Pharma has a fifty-two week low of $0.08 and a fifty-two week high of $0.53.
Get China Pharma alerts:China Pharma (NYSEAMERICAN:CPHI – Get Rating) last issued its earnings results on Monday, November 14th. The company reported ($0.02) earnings per share for the quarter. The firm had revenue of $1.97 million for the quarter. China Pharma had a negative return on equity of 81.00% and a negative net margin of 45.71%.
China Pharma Company Profile
(Get Rating)China Pharma Holdings, Inc engages in the development, manufacture, and marketing of pharmaceutical products. The firm's product portfolio includes Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases, Comprehensive Healthcare, and Protective Products.
See Also
- Get a free copy of the StockNews.com research report on China Pharma (CPHI)
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
- Does it Matter Folks Aren't "Starry-Eyed" Over Pepsi's New Soda?
Receive News & Ratings for China Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
China Pharma Holdings, Inc. (NYSEAMERICAN:CPHI – Get Rating) saw a significant drop in short interest during the month of December. As of December 30th, there was short interest totalling 244,600 shares, a drop of 51.8% from the December 15th total of 507,100 shares. Based on an average daily volume of 2,160,000 shares, the short-interest ratio is presently 0.1 days. Currently, 0.9% of the company's stock are short sold.
中国制药控股有限公司(纽约证券交易所代码:CPHI — GET Rating)在12月份的空头利率大幅下降。截至12月30日,空头利率共计244,600股,较12月15日的507,100股下降了51.8%。根据2,160,000股的平均每日成交量,目前的空头利率为0.1天。目前,该公司0.9%的股票被卖空。
China Pharma Stock Performance
中国制药股票表现
CPHI remained flat at $0.11 during trading on Wednesday. 1,588,857 shares of the company were exchanged, compared to its average volume of 1,853,631. The firm has a market capitalization of $5.43 million, a P/E ratio of -1.31 and a beta of 0.62. China Pharma has a fifty-two week low of $0.08 and a fifty-two week high of $0.53.
CPHI在周三的交易中持平至0.11美元。该公司交换了1,588,857股股票,而平均交易量为1,853,631股。该公司的市值为543万美元,市盈率为-1.31,beta值为0.62。中国制药创下五十二周低点0.08美元,五十二周高点为0.53美元。
China Pharma (NYSEAMERICAN:CPHI – Get Rating) last issued its earnings results on Monday, November 14th. The company reported ($0.02) earnings per share for the quarter. The firm had revenue of $1.97 million for the quarter. China Pharma had a negative return on equity of 81.00% and a negative net margin of 45.71%.
中国制药(纽约证券交易所美国股票代码:CPHI — 获取评级)最后一次发布财报是在11月14日星期一。该公司报告了本季度每股收益(0.02美元)。该公司本季度的收入为197万美元。中国制药的股本回报率为负81.00%,负净利润率为45.71%。
China Pharma Company Profile
中国制药公司简介
China Pharma Holdings, Inc engages in the development, manufacture, and marketing of pharmaceutical products. The firm's product portfolio includes Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases, Comprehensive Healthcare, and Protective Products.
China Pharma Holdings, Inc从事药品的开发、制造和营销。该公司的产品组合包括中枢神经系统(CNS)和脑心血管疾病、抗感染和呼吸系统疾病、消化系统疾病、综合医疗保健和保护产品。
See Also
另见
- Get a free copy of the StockNews.com research report on China Pharma (CPHI)
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
- Does it Matter Folks Aren't "Starry-Eyed" Over Pepsi's New Soda?
- 免费获取 StockNews.com 关于中国制药 (CPHI) 的研究报告
- 股市下滑,经济报告描绘了经济的阴暗前景
- Nu Holdings 的股票与沃伦·巴菲特有什么关系?
- J.B. Hunt 持平,物流公司成为人们关注的焦点
- 英特尔股票即将爆发吗?
- 人们不对百事可乐的新苏打水 “满眼相看” 有关系吗?
Receive News & Ratings for China Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收《中国医药日报》的新闻和评级 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收中国制药及相关公司的最新新闻和分析师评级的简要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧